Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Grothey

Showing results (191-200 of 304) with videos related to

Pageof 31
Sort By:
Seminars in Oncology|October 22, 2008
North Central Cancer Treatment Group--achievements and perspectivesAxel Grothey, Alex A Adjei, Steve R Alberts, et al.
The Oncologist|September 4, 2009
Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort studyMark Kozloff, Marianne Ulcickas Yood, Jordan Berlin, et al.
Pharmacoepidemiology and Drug Safety|May 17, 2014
Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort studyAxel Grothey, E Dawn Flick, Allen L Cohn, et al.
The Oncologist|April 21, 2018
Outcome of Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Mayo Clinic ExperienceZhaohui Jin, Cristobal T Sanhueza, Benny Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2011
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841Jan Franko, Qian Shi, Charles D Goldman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapyScott Kopetz, George J Chang, Michael J Overman, et al.
Cancer Chemotherapy and Pharmacology|September 23, 2024
Phase I-II study of OBI-888, a humanized monoclonal IgG1 antibody against the tumor-associated carbohydrate antigen Globo H, in patients with advanced solid tumorsApostolia Maria Tsimberidou, Axel Grothey, Darren Sigal, et al.
The Oncologist|February 16, 2018
A Curative-Intent Trimodality Approach for Isolated Abdominal Nodal Metastases in Metastatic Colorectal Cancer: Update of a Single-Institutional ExperienceBenny Johnson, Zhaohui Jin, Michael G Haddock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 20, 2008
Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trialsHendrik-Tobias Arkenau, Dirk Arnold, Jim Cassidy, et al.
Therapeutic Advances in Medical Oncology|March 24, 2020
Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance)Hao Xie, Jacqueline M Lafky, Bruce W Morlan, et al.
Pageof 31

Showing results (191-200 of 304) with videos related to

Sort By:
Pageof 31
Seminars in Oncology|October 22, 2008
North Central Cancer Treatment Group--achievements and perspectivesAxel Grothey, Alex A Adjei, Steve R Alberts, et al.
The Oncologist|September 4, 2009
Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort studyMark Kozloff, Marianne Ulcickas Yood, Jordan Berlin, et al.
Pharmacoepidemiology and Drug Safety|May 17, 2014
Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort studyAxel Grothey, E Dawn Flick, Allen L Cohn, et al.
The Oncologist|April 21, 2018
Outcome of Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Mayo Clinic ExperienceZhaohui Jin, Cristobal T Sanhueza, Benny Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2011
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841Jan Franko, Qian Shi, Charles D Goldman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapyScott Kopetz, George J Chang, Michael J Overman, et al.
Cancer Chemotherapy and Pharmacology|September 23, 2024
Phase I-II study of OBI-888, a humanized monoclonal IgG1 antibody against the tumor-associated carbohydrate antigen Globo H, in patients with advanced solid tumorsApostolia Maria Tsimberidou, Axel Grothey, Darren Sigal, et al.
The Oncologist|February 16, 2018
A Curative-Intent Trimodality Approach for Isolated Abdominal Nodal Metastases in Metastatic Colorectal Cancer: Update of a Single-Institutional ExperienceBenny Johnson, Zhaohui Jin, Michael G Haddock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 20, 2008
Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trialsHendrik-Tobias Arkenau, Dirk Arnold, Jim Cassidy, et al.
Therapeutic Advances in Medical Oncology|March 24, 2020
Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance)Hao Xie, Jacqueline M Lafky, Bruce W Morlan, et al.
Pageof 31